Your browser doesn't support javascript.
loading
Long-term treatment with nebulized colistin in oncological patients with recurrent respiratory infections.
Suanzes, Paula; Aguilar-Company, Juan; Rodríguez-González, Esther; Martín-Gómez, M Teresa; Gómez-Domingo, M Rosa; Ruiz-Camps, Isabel.
Afiliación
  • Suanzes P; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Aguilar-Company J; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Oncology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Electronic address: juanaguilarcompany@gmail.com.
  • Rodríguez-González E; Pneumology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Martín-Gómez MT; Microbiology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Gómez-Domingo MR; Pharmacy Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Ruiz-Camps I; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Med Clin (Barc) ; 159(9): 432-436, 2022 11 11.
Article en En, Es | MEDLINE | ID: mdl-35618498
OBJECTIVES: To assess the efficacy of long-term treatment with nebulized colistin in reducing the number of respiratory infections, emergency consultations and hospitalizations in oncological patients. METHODS: A retrospective, observational, single-centre study including patients with solid or haematologic malignancies, or pulmonary GVHD after HSTC who received treatment with nebulized colistin for at least six-months to prevent recurrent respiratory infections (July 2010 to June 2017). RESULTS: Twelve patients were included (median age: 54.4, range: 23-85), 7 with solid malignancies and 5 with haematologic malignancies (2 with pulmonary GVHD). Pseudomonas aeruginosa was the most frequent microorganism in sputum cultures (11/12 patients), all strains were susceptible to colistin. There was a statistically significant reduction (p=0.01) in respiratory infections in the six-month period after starting colistin (median: 1, range: 0-4) compared to the six-month period before (median: 4, range: 1-8). There was also a reduction in emergency consultations (precolistin: median: 1.50, range: 0-3; postcolistin: median: 0, range: 0-3) and hospitalizations (precolistin: median: 1.50, range: 0-3; postcolistin: median: 0, range: 0-3) due to respiratory infections. No colistin-resistant strains were identified. CONCLUSIONS: Long-term treatment with nebulized colistin may be useful to reduce the number of exacerbations in oncological patients with recurrent respiratory infections.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por Pseudomonas / Infecciones del Sistema Respiratorio / Neoplasias Hematológicas / Enfermedad Injerto contra Huésped Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans / Middle aged Idioma: En / Es Revista: Med Clin (Barc) Año: 2022 Tipo del documento: Article País de afiliación: España Pais de publicación: España
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por Pseudomonas / Infecciones del Sistema Respiratorio / Neoplasias Hematológicas / Enfermedad Injerto contra Huésped Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans / Middle aged Idioma: En / Es Revista: Med Clin (Barc) Año: 2022 Tipo del documento: Article País de afiliación: España Pais de publicación: España